Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Scopolamine Field Test for Motion Sickness
NCT05852730Phase 2Recruiting
- Sponsor
- Defender Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Sep 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of scopolamine in motion sickness, sponsored by Defender Pharmaceuticals. Started Aug 2021; status: recruiting.
02
Drugs
scopolamine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT05852730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852730.